Director/PDMR Shareholding
Summary by AI BETAClose X
Haleon plc: Director/PDMR Shareholding
5 September 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
This notification sets out the details of the grant of Haleon share awards over Ordinary Shares and American Depositary Shares (ADS) made to PDMRs under the Haleon Share Value Plan and Performance Share Plan.
The Performance Share Plan (Interim) awards are subject to continued employment and performance conditions over the performance period ending on 31 December 2027 (vesting in March 2028). Performance targets were disclosed in the Annual Report and Form 20-F 2024.
The Share Value Plan (Buyout) awards are subject to continued employment.
All awards were made in line with the principles of Haleon's Directors' Remuneration Policy and are subject to malus and clawback provisions.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Carl Haney |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief R&D Officer |
||||
|
b)
|
Initial notification /Amendment |
Initial Notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name
|
Haleon plc |
||||
|
b)
|
LEI
|
549300PSB3WWEODCUP19 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.01 each |
||||
|
|
|
|||||
|
Identification code |
GB00BMX86B70 |
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction
|
(i) Grant of a conditional award under the Haleon plc Performance Share Plan (Interim) (ii) Grant of a conditional award under the Haleon plc Share Value Plan (Buyout) |
||||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
(i) |
Nil |
641,096 |
|
|
|
|
|
(ii) |
Nil |
192,571 |
|
|
|
|
|
|
|
|
||
|
d)
|
Aggregated information |
|
||||
|
|
|
|||||
|
- Aggregated volume |
833,667 |
|||||
|
|
|
|||||
|
- Price |
Nil |
|||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
4 September 2025 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue
|
||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Nathalie Gerschtein |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
President North America |
||||
|
b)
|
Initial notification /Amendment |
Initial Notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name
|
Haleon plc |
||||
|
b)
|
LEI
|
549300PSB3WWEODCUP19 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument |
Haleon plc American Depositary Shares (ADS) |
||||
|
|
|
|||||
|
Identification code |
US4055521003 |
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction
|
(i) Grant of a conditional award under the Haleon plc Performance Share Plan (Interim) (ii) Grant of a conditional award under the Haleon plc Share Value Plan (Buyout) |
||||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
(i) |
Nil |
244,400 |
|
|
|
|
|
(ii) |
Nil |
405,911 |
|
|
|
|
|
|
|
|
||
|
d)
|
Aggregated information |
|
||||
|
|
|
|||||
|
- Aggregated volume |
650,311 |
|||||
|
|
|
|||||
|
- Price |
Nil |
|||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
4 September 2025 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue
|
||||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 3 hours ago Savannah Energy
- 4 hours ago Buccaneer Energy PLC
- 4 hours ago Savannah Energy
- 4 hours ago Carclo
- 5 hours ago Schroder Japan Growth Fund